Evidence map›Paper›PMID 38203489›Full record

ArticleInternational journal of molecular sciences2023

Diagnostic Algorithm to Subclassify Atypical Spitzoid Tumors in Low and High Risk According to Their Methylation Status.

Jose Francisco González-Muñoz, Beatriz Sánchez-Sendra, Carlos Monteagudo

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Defensive medicine in dermatological practice - Dermatopathology as a mirror of structural challenges.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jose Francisco González-MuñozSkin Cancer Research Group, Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.ORCID 0000-0002-9832-3355
Beatriz Sánchez-SendraSkin Cancer Research Group, Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.ORCID 0000-0002-9115-9249
Carlos MonteagudoSkin Cancer Research Group, Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.ORCID 0000-0002-9381-9976

Funding

Asociación Española Contra el Cáncer Reto EverestInstituto de Salud Carlos III PI17/02019Instituto de Salud Carlos III PI20/00094
6 · The paper itself

Abstract

Current diagnostic algorithms are insufficient for the optimal clinical and therapeutic management of cutaneous spitzoid tumors, particularly atypical spitzoid tumors (AST). Therefore, it is crucial to identify new markers that allow for reliable and reproducible diagnostic assessment and can also be used as a predictive tool to anticipate the individual malignant potential of each patient, leading to tailored individual therapy. Using Reduced Representation Bisulfite Sequencing (RRBS), we studied genome-wide methylation profiles of a series of Spitz nevi (SN), spitzoid melanoma (SM), and AST. We established a diagnostic algorithm based on the methylation status of seven cg sites located in

Indexed as

MelanomaNevusSkin NeoplasmsAlgorithmsHumansMethylationalgorithmmelanomamethylationnovel biomarkersSpitzSpitzoid melanocytic tumors

Identifiers

PMID38203489
PMCPMC10779069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.